相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Aminoisoquinoline benzamides, FLT3 and Src-family kinase inhibitors potently inhibit proliferation of acute myeloid leukemia cell lines
Elizabeth Larocque et al.
FUTURE MEDICINAL CHEMISTRY (2017)
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
Masamichi Mori et al.
INVESTIGATIONAL NEW DRUGS (2017)
Opportunities and challenges in phenotypic drug discovery: an industry perspective
John G. Moffat et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Identification of New FLT3 Inhibitors That Potently Inhibit AML Cell Lines via an Azo Click-It/Staple-It Approach
Xiaochu Ma et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis
Jason Gotlib et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Drug resistance in cancer: molecular evolution and compensatory proliferation
Ran Friedman
ONCOTARGET (2016)
Cardiotoxicity associated with targeted cancer therapies (Review)
Zi Chen et al.
MOLECULAR AND CLINICAL ONCOLOGY (2016)
The kinome 'at large' in cancer
Emmy D. G. Fleuren et al.
NATURE REVIEWS CANCER (2016)
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
C. C. Smith et al.
LEUKEMIA (2015)
FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia
Michael R. Grunwald et al.
SEMINARS IN HEMATOLOGY (2015)
FDA-approved small-molecule kinase inhibitors
Peng Wu et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia
Houda Alachkar et al.
ONCOTARGET (2015)
Inhibition of c-Kit by tyrosine kinase inhibitors
Allison Galanis et al.
HAEMATOLOGICA (2015)
AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and dose dependent reduction of tyrosine kinase activity in acute myeloid leukemia
Anna Eriksson et al.
BIOCHEMICAL PHARMACOLOGY (2014)
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
Allison Galanis et al.
BLOOD (2014)
Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia
Kathleen Keegan et al.
MOLECULAR CANCER THERAPEUTICS (2014)
TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis
Yo Matsuo et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
Seth A. Wander et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2014)
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia
Eric I. Zimmerman et al.
BLOOD (2013)
Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Status
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The Role of FLT3 Kinase as an AML Therapy Target
Micha Beffinger et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
FLT3 inhibitors: a story of the old and the new
Amir Fathi et al.
CURRENT OPINION IN HEMATOLOGY (2011)
The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations
T. Odgerel et al.
ONCOGENE (2008)
Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition
Katherine Holmes et al.
CELLULAR SIGNALLING (2007)
Protein kinases as targets for cancer treatment
Georgios Giamas et al.
PHARMACOGENOMICS (2007)
The role of VEGF receptors in angiogenesis;: complex partnerships
S Cébe-Suarez et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2006)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
分享论文
